View Older Stories View More Recent Stories

Jan 10, 2024 09:45PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jan 4, 2024 04:01PM Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization
Jan 4, 2024 10:00AM Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
Jan 3, 2024 07:00AM Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Dec 28, 2023 09:00AM Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 21, 2023 09:00AM Kinaset Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 19, 2023 02:09PM Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors
Dec 14, 2023 08:14PM Form 4 Disc Medicine, Inc. For: Dec 12 Filed by: Atlas Venture Fund X, L.P.
Dec 13, 2023 07:00AM Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Dec 12, 2023 06:04PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Dec 12, 2023 06:01PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 12, 2023 08:00AM Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments
Dec 10, 2023 12:30PM Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​
Dec 7, 2023 09:00AM Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Dec 4, 2023 08:00AM K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Nov 22, 2023 09:00AM Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
Nov 16, 2023 07:06AM Homology Medicines (FIXX) and Q32 Bio to Merge
Nov 16, 2023 07:05AM Q32 Bio and Homology Medicines Announce Merger Agreement
Nov 15, 2023 08:00AM K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
Nov 13, 2023 04:16PM Form SC 13D Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 13, 2023 04:15PM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 13, 2023 10:52AM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Nov 13, 2023 10:46AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 13, 2023 10:43AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 13, 2023 10:41AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 13, 2023 10:37AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 7, 2023 09:06PM Form 3 Korro Bio, Inc. For: Nov 03 Filed by: Atlas Venture Associates XI, L.P.
Nov 3, 2023 03:31PM UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Nov 3, 2023 12:19PM Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Nov 2, 2023 12:05PM Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
Oct 31, 2023 12:01PM Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
Oct 26, 2023 06:00AM Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Oct 25, 2023 08:00AM Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning
Oct 24, 2023 08:00AM Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
Oct 11, 2023 09:00AM Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa
Oct 10, 2023 03:30AM Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
Sep 21, 2023 04:45PM Form SC 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 18, 2023 05:00PM Form 4 Disc Medicine, Inc. For: Sep 14 Filed by: Atlas Venture Associates X, LLC
Sep 18, 2023 06:31AM Verve Therapeutics (VERV) Appoints Frederick T. Fiedorek as Chief Medical Officer
Sep 18, 2023 06:30AM Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
Sep 15, 2023 06:44PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 15, 2023 04:57PM Form SC 13D/A Dianthus Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Sep 14, 2023 05:33PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 7, 2023 06:30AM Mariana Oncology Announces $175 Million Series B Financing
Sep 6, 2023 07:00AM Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
Aug 16, 2023 06:56PM Form 4 Disc Medicine, Inc. For: Aug 14 Filed by: Atlas Venture Associates Opportunity I, L.P.
Aug 15, 2023 06:33PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 15, 2023 06:18PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 14, 2023 05:04PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 11, 2023 04:14PM Form 13F-HR Atlas Venture Life Scien For: Jun 30
View More Recent Stories View Older Stories